Replication Data for: Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, and JN.1.4, using samples from two health demographic surveillance systems in Kenya

SARS-CoV-2 virus continues to mutate leading to emerging variants that escape immunity previously raised by vaccination and/or infection by earlier variants. We used genomic data to identify the most prevalent Kenyan and global variants between May 2023 and March 2024 and performed pseudoviruses neutralization assays on samples collected from two health demographic surveillance systems in Kenya (n=54), for vaccine induced immunity against circulating variants EG.5.1, FY.4 19, BA.2.86, JN.1, and JN.1.4.

As a comparator, we used natural wildtype infection samples (n=20) collected in 2020 at the onset of the pandemic and confirmed to be PCR positive for SARS-CoV-2. We also assessed the effects of different doses of vaccine, age, sex, and type of vaccine on antibody-neutralizing titers.